Trial PROSPERs China's fight against advancing prostate cancer
Trial PROSPERs China’s fight against advancing prostate cancer New results from the PROSPER trial helped persuade the Chinese government to approve enzalutamide for adult patients diagnosed with advanced non-metastatic castration-resistant prostate cancer, Peter Doyle reports It might be coincidental. But eight months after a joint study by the Peking First University Hospital and National Urological Cancer Center of China in Beijing found a lack of effective therapies in the world’s most ...
United States Hiroshi Hamaguchi Andrew Krivoshik Peter Doyle Chinese Journal Of Cancer Research First University Hospital
Source: imt.ie